Funder
National Cancer Institute Cancer Center Support
Astellas Pharma, Inc.
Seagen Inc.
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, et al. Enfortumab vedotin antibody-drug conjugate targeting Nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. 2016;76(10):3003–13.
2. Enfortumab vedotin-ejfv [package insert]. Northbrook, IL: 2023.
3. Rosenberg J, Sridhar SS, Zhang J, Smith D, Ruether D, Flaig TW, et al. EV-101: A phase I study of single-agent enfortumab vedotin in patients eith Nectin-4-positive solid tumors, including metastatic urothelial carcinoma. J Clin Oncol. 2020;38(10):1041–9.
4. Liu AB, Olson D, Snead K, Gosink J, Tenn E, Zaval M, et al., editors. Enfortumab vedotin, an anti-Nectin-4 ADC demonstrates bystander cell killing and immunogenic cell death anti-tumor activity mechanisms of action in urothelial cancers. American Association of Cancer Research Virtual Meeting II; 22–24 June 2020; Virtual.
5. Olson D, Younan P, Liu B, Blahnik-Fagan G, Gosink J, Snead K, et al. 1187 Enfortumab vedotin induces immunogenic cell death, elicits antitumor immune memory, and shows enhanced preclinical activity in combination with immune checkpoint inhibitors. J Immunother Cancer. 2022;10:A1231.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献